Exscientia

Exscientia's motivation is to find faster and smarter methods to discover new and better drugs. Exscientia will allow people to live more healthy and productive lives by actively employing AI to precision engineer medicines more quickly and efficiently. To handle this challenge, they are reimagining how drug discovery is implemented, combining cutting-edge AI techniques with experimental innovation to create a new set of drug discovery processes.

Exscientia, a company founded in 2012, is at the forefront of the growth of pharmatech, a field that combines complex drug discovery with sophisticated AI applications. Exscientia was the first business to automate drug development and the first to introduce a molecule created by artificial intelligence into clinical testing.

Exscientia, as a full stack AI drug discovery business, focuses on AI design as well as precision data generation. These, when combined, increase the strength and fidelity of the integrated AI and machine learning systems. Exscientia is able to greatly accelerate the pre-clinical drug discovery stage, enabling the delivery of novel treatments to patients worldwide, by focusing on both design and experiment.

Founded: 2012

Headquarter: Oxford, Oxfordshire

Website: https://exscientia.ai